Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive‐resistant differentiated thyroid cancer

Abstract

The entity of multiple neoplasms is not rare or new, having been first described by Billroth in 1889 1 and further reported on by Owen 2 in 1921.Multiple primary malignant neoplasm (MPMN) is defined as more than one primary histologically distinct malignant tumor that occurs in a single individual and may include solid cancers and hematologic malignancies. MPMN can be divided into two categories (based on International Association of Cancer Registries and International Agency for Research on Cancer definitions):(i) synchronous -malignancies occurring within 6 months of a previous malignant neoplasm; and (ii) metachronous -defined as malignancies occurring more than 6 months apart. 3 The prevalence of MPMN is reported to be 2%-17%. 3-5 It is expected that the prevalence of MPMN (mainly metachronous) will increase in the future due to increasingly aging populations combined with improved cancer survival, improved diagnostic tests, increasingly sophisticated treatment, better screening, and enhanced surveillance of patients with previous cancer.

Association Between the XRCC1, GSTM1, and GSTT1 Polymorphisms in Model of Thyroid Cancer: A Meta-Analysis

“…The etiology of thyroid cancer remains uncertain. However, several factors have been associated with an increased risk of developing thyroid cancer, including exposure to radiation, metabolic syndrome (characterized by obesity, hypertension, hyperlipidemia, and diabetes), unhealthy diet and lifestyle, and environmental pollution [39][40][41]. Implementing measures to reduce radiation exposure, controlling blood pressure, blood lipid levels, blood sugar levels, and weight, as well as adopting healthier living habits, may help to lower the risk of thyroid cancer [42].…”